Technical Analysis for GLTO - Galecto, Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| F | 10.0 | 8.11% | 0.75 |
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | N/A | Down | Down |
| Historical GLTO trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| New 52 Week Closing Low | Bearish | 8.22% | |
| Calm After Storm | Range Contraction | 8.22% | |
| Lower Bollinger Band Walk | Weakness | 8.22% | |
| New 52 Week Low | Weakness | 8.22% | |
| Outside Day | Range Expansion | 8.22% | |
| Wide Bands | Range Expansion | 8.22% | |
| Below Lower BB | Weakness | 8.22% | |
| Down 3 Days in a Row | Weakness | 8.22% | |
| Down 4 Days in a Row | Weakness | 8.22% | |
| Lower Bollinger Band Touch | Weakness | 8.22% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
| Alert | Time | |
|---|---|---|
| Gapped Up (Full) | 34 minutes ago | |
| Rose Above Previous Day's High | 34 minutes ago | |
| Rose Above Lower Bollinger Band | 34 minutes ago | |
| Up 5% | 34 minutes ago | |
| Up 3% | 34 minutes ago |
Get this analysis on your stocks daily!
- Earnings date: ???
Galecto, Inc. Description
Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB0139, an inhaled inhibitor of galectin-3 that is in Phase IIb clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis, a life-threatening progressive fibrotic disease of the lung. Its products also comprise GB2064, which is in Phase I/IIa for the treatment of myelofibrosis; and GB1211, a selective oral galectin-3 inhibitor that is in Phase I/IIa for the treatment of fibrosis related to non-alcoholic steatohepatitis, as well as development of other related indications, including cancer. Galecto, Inc. was founded in 2011 and is headquartered in Copenhagen, Denmark.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Cancer Clinical Medicine Biology Alcohol Inflammation Steatohepatitis Non Alcoholic Fatty Liver Disease Idiopathic Pulmonary Fibrosis Progressive Pulmonary Fibrosis Fibrosis Related Disease Related Diseases Breakthrough Therapy Copenhagen Fibrotic Disease Lectins mTOR Galectin Lung Diseases Myelofibrosis Treatment Of Fibrosis Galectin 3 Galecto Biotech
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 17.99 |
| 52 Week Low | 9.02 |
| Average Volume | 18,985 |
| 200-Day Moving Average | 0.00 |
| 50-Day Moving Average | 12.34 |
| 20-Day Moving Average | 11.56 |
| 10-Day Moving Average | 10.84 |
| Average True Range | 0.76 |
| ADX | 24.45 |
| +DI | 8.44 |
| -DI | 30.52 |
| Chandelier Exit (Long, 3 ATRs ) | 10.87 |
| Chandelier Exit (Short, 3 ATRs ) | 11.29 |
| Upper Bollinger Band | 13.62 |
| Lower Bollinger Band | 9.51 |
| Percent B (%b) | -0.06 |
| BandWidth | 35.53 |
| MACD Line | -0.76 |
| MACD Signal Line | -0.52 |
| MACD Histogram | -0.2462 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 10.65 | ||||
| Resistance 3 (R3) | 10.72 | 10.34 | 10.41 | ||
| Resistance 2 (R2) | 10.34 | 9.98 | 10.30 | 10.33 | |
| Resistance 1 (R1) | 9.79 | 9.76 | 9.60 | 9.72 | 10.26 |
| Pivot Point | 9.41 | 9.41 | 9.31 | 9.37 | 9.41 |
| Support 1 (S1) | 8.86 | 9.05 | 8.67 | 8.79 | 8.24 |
| Support 2 (S2) | 8.48 | 8.83 | 8.44 | 8.17 | |
| Support 3 (S3) | 7.93 | 8.48 | 8.09 | ||
| Support 4 (S4) | 7.86 |
